非整倍体植入前遗传学检测:我们评估的结局正确吗?
该文针对PGT-A的获益争议,评估了2012-2019年最新的随机对照试验。六项研究中仅两项报告了每启动周期的累积活产率,且均为统计学非显著结果。文章指出,关注首次胚胎移植结局而非累积结局会错误地将PGT-A误读为具有更优结局,而其真实获益并未被证实。
要点
- 六项RCT中仅两项报告每启动周期累积活产率,均为非显著结果。
- 以首次移植结局替代累积结局会高估PGT-A的临床获益。
- PGT-A无法真正改善胚胎库的整体妊娠结局。
核心结论
- 关注首次胚胎移植结局而非累积结局会错误地将PGT-A解读为具有更优结局,其真实获益未被证实。
- PGT-A不能真正改善胚胎库的整体妊娠结局。
研究设计与样本
- 对2012-2019年发表的PGT-A相关随机对照试验进行评估与量化分析。
主要发现
- 六项随机对照试验中仅两项报告了每启动周期的累积活产率,且均为统计学非显著结果。
临床怎么用
- 评估PGT-A获益时应优先参考每启动周期的累积活产率等累积结局指标。
局限性
- 多数随机对照试验未报告每启动周期的累积活产率,影响对PGT-A真实获益的判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Questions continue to be raised regarding the benefit of genetic assessment of embryos prior to transfer in IVF, specifically with regards to preimplantation genetic testing for aneuploidy (PGT-A). To evaluate and quantify these concerns, we appraised the most recent (2012-2019) randomized controlled trials on the topic. Only two of these six studies listed cumulative live birth rates per started cycle, with both eliciting a statistically non-significant result. This article describes the concern that a focus on results from the first embryo transfer compared to cumulative outcomes falsely construes PGT-A as having superior outcomes, whilst its true benefit is not confirmed, and it cannot actually improve the true pregnancy outcome of an embryo pool.
引用
- Kemper JM, Wang R, Rolnik DL, et al. Preimplantation genetic testing for aneuploidy: are we examining the correct outcomes? Hum Reprod. 2020. PMID: 32964938. doi:10.1093/humrep/deaa224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。